Unesbulin for Leiomyosarcoma
This trial will compare two different treatments for leiomyosarcoma, a type of cancer. One treatment will be the standard of care, and the other will be a new treatment that includes a drug called unesbulin. The trial will look at whether the new treatment is more effective and has fewer side effects than the standard treatment.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2016 Phase 3 trial • 854 Patients • NCT00003389
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are researchers currently enrolling people into this trial?
"The clinical trial mentioned is still searching for participants and was first posted on May 23rd, 2022. The last update to the trial was on September 21st, 2022."
How many research facilities are managing this clinical trial?
"Patients can enroll at various hospitals and research centres, some of which include The Trustees of Columbia University in New York, New York, University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, and Washington University in Saint Louis, Missouri."
How many individuals are receiving care in this clinical trial?
"The sponsor, PTC Therapeutics, needs to enroll 345 patients that meet the basic requirements for the trial. The trial will take place in New York, New York at The Trustees of Columbia University and University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania."